H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia (AKBA) with a Buy rating and $8 price target The company’s approved product Vafseo indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months, continues to gain uptake among dialysis organizations, the analyst tells investors in a research note. The firm believes the ongoing Vafseo launch can offset generic impact on the company’s other approved product Auryxia, which has focused commercially on the hyperphosphatemia indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial
- Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Akebia Therapeutics Reports Strong Q1 2025 Performance
- Akebia Therapeutics Reports Strong Vafseo Launch Success
- Akebia reports Q1 EPS 3c vs (9c) last year